// App-Quantinova.ai

11023 : Relationship between RECIST response and variation of circulating tumor cells (CTC) for patients enrolled in phase I trials.

Researchers

Presenter

  • Christophe Massard

Principal Investigators

  • Franoise Farace

  • Francois Clement Bidard

  • Jean-Philippe Spano

  • Charles Ferte

  • Jean-Charles Soria

  • Ludovic Lacroix

Medical Centers

  • Department of Medical Oncology, Pitie-Salpetriere University Hospital - INSERM UMR_S 1136, Paris, France

  • Department of Medical Oncology, Institut Gustave Roussy, Villejuif, FranceGustave Roussy Institute, Villejuif, FranceGustave Roussy, University Paris Sud, Villejuif, France

  • Institut Curie, Paris Cedex, France

  • Department of Medical Oncology, Institut Curie, Saint-Cloud, France

  • Institut Gustave-Roussy, Villejuif, France

  • Department of Biopathology. Gustave Roussy Cancer Campus, Villejuif, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • N/A

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved